Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo

I Pizzitola, K Rouault-Pierre, F Lassailly, S Tettamanti… - Leukemia, 2014 - nature.com
As significant numbers of acute myeloid leukemia (AML) patients are still refractory to
conventional therapies or experience relapse, immunotherapy using T cells expressing …
被引用次数：338 相关文章

[引用][C] Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo

I Pizzitola, F Anjos-Afonso, K Rouault-Pierre… - Leukemia, 2014 - cir.nii.ac.jp
Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute
myeloid leukemia cells in vivo | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …

Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo

I Pizzitola, F Anjos-Afonso, K Rouault-Pierre… - …, 2014 - pubmed.ncbi.nlm.nih.gov
As significant numbers of acute myeloid leukemia (AML) patients are still refractory to
conventional therapies or experience relapse, immunotherapy using T cells expressing …

Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo

I Pizzitola, F Anjos-Afonso, K Rouault-Pierre… - Leukemia, 2014 - go.gale.com
As significant numbers of acute myeloid leukemia (AML) patients are still refractory to
conventional therapies or experience relapse, immunotherapy using T cells expressing …

Chimeric Antigen Receptors against CD33/CD123 antigens efficiently target primary Acute Myeloid Leukemia cells in vivo

I Pizzitola, F Anjos Afonso, K Rouault Pierre, F Lassailly… - LEUKEMIA, 2014 - boa.unimib.it
As significant numbers of acute myeloid leukemia (AML) patients are still refractory to
conventional therapies or experience relapse, immunotherapy using T-cells expressing …

Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo.

I Pizzitola, F Anjos-Afonso, K Rouault-Pierre… - Leukemia, 2014 - europepmc.org
As significant numbers of acute myeloid leukemia (AML) patients are still refractory to
conventional therapies or experience relapse, immunotherapy using T cells expressing …

Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo.

I Pizzitola, F Anjos-Afonso… - Leukemia …, 2014 - search.ebscohost.com
As significant numbers of acute myeloid leukemia (AML) patients are still refractory to
conventional therapies or experience relapse, immunotherapy using T cells expressing …
[PDF] researchgate.net

[PDF][PDF] Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo

I Pizzitola, F Anjos-Afonso, K Rouault-Pierre… - Leukemia, 2014 - researchgate.net
Despite progresses in the treatment of acute myeloid leukemia (AML), a significant number
of patients are still refractory to their treatment or experience relapse. Hence, it is crucial to …

Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo

I Pizzitola, F Anjos-Afonso, K Rouault-Pierre… - Leukemia, 2014 - orca.cardiff.ac.uk
As significant numbers of acute myeloid leukemia (AML) patients are still refractory to
conventional therapies or experience relapse, immunotherapy using T cells expressing …

Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo

I Pizzitola, F Anjos-Afonso, K Rouault-Pierre… - Leukemia, 2014 - orca.cardiff.ac.uk
As significant numbers of acute myeloid leukemia (AML) patients are still refractory to
conventional therapies or experience relapse, immunotherapy using T cells expressing …